Leprosy

References

Key articles

World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.Full text

World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Full text

WHO Leprosy Elimination Group. A guide to eliminate leprosy as a public health problem. 2000 [internet publication].Full text

WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.Full text  Abstract

Reference articles

1. World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

2. Ridley DS Jopling.WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255-273. Abstract

3. World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.Full text

4. Han XY, Jessurun J. Severe leprosy reactions due to Mycobacterium lepromatosis. Am J Med Sci. 2013;345:65-9.Full text  Abstract

5. Kamath S, Vaccaro SA, Rea TH, et al. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71:795-803. Abstract

6. World Health Organization - Global Leprosy Programme. Global leprosy strategy 2016-2020: accelerating towards a leprosy-free world. 2016 [internet publication].Full text

7. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409:1007-1011.Full text  Abstract

8. Han XY, Sizer KC, Tan HH. Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. J Drugs Dermatol. 2012;11:168-172. Abstract

9. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338-381.Full text  Abstract

10. Rees RJ, McDougall AC. Airborne infection with Mycobacterium leprae in mice. J Med Microbiol. 1977;10:63-68. Abstract

11. Chehl S, Job CK, Hastings RC. Transmission of leprosy in nude mice. Am J Trop Med Hyg. 1985;34:1161-1166. Abstract

12. Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364:1626-1633.Full text  Abstract

13. Avanzi C, Del-Pozo J, Benjak A, et al. Red squirrels in the British Isles are infected with leprosy bacilli. Science. 2016 Nov 11;354(6313):744-47. Abstract

14. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277-279. Abstract

15. Mira MT, Alcaïs A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427:636-640. Abstract

16. Misch EA, Berrington WR, Vary JC Jr, et al. Leprosy and the human genome. Microbiol Mol Biol Rev. 2010;74:589-620.Full text  Abstract

17. Guinto RS, Rodriguez JN, Doull JA, et al. The trend of leprosy in Cordova and Talisay, Cebu Province, Philipines. Int J Lepr. 1954;22:409-430. Abstract

18. Noordeen SK, Neelan PN. Extended studies on chemoprophylaxis against leprosy. Indian J Med Res. 1978;67:515-527. Abstract

19. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348:17-24. Abstract

20. Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet. 1992;339:446-450. Abstract

21. Gupte MD, Vallishayee RS, Anantharaman DS, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr. 1998;70:369-388. Abstract

22. Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6:162-170. Abstract

23. Zodpey SP. Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J Dermatol Venereol Leprol. 2007;73:86-93. Abstract

24. Zodpey SP. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health. 2004;48:70-77. Abstract

25. Kartikeyan S, Chaturvedi RM, Deo MG. Anti-leprosy vaccines: current status and future prospects. J Postgrad Med. 1991;37:198-204.Full text  Abstract

26. Montestruc E, Berdonneau R. Two cases of leprosy in infants in Martinique [in French]. Bull Soc Pathol Exot Filiales. 1954;47:781-783. Abstract

27. World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Full text

28. WHO Leprosy Elimination Group. A guide to eliminate leprosy as a public health problem. 2000 [internet publication].Full text

29. Lazo-Porras M, Prutsky GJ, Barrionuevo P, et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC Infect Dis. 2020 Jan 20;20(1):62.Full text  Abstract

30. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Full text

31. US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Full text

32. US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Oct 2018 [internet publication].Full text

33. Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019 Jun 1;155(6):666-72.Full text  Abstract

34. Van Veen NH, Nicholls PG, Smith WC, et al. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev. 2016 May 23;(5):CD005491.Full text  Abstract

35. WHO Expert Committee on Leprosy. 7th report. World Health Organ Tech Rep Ser. 1998;874:20.Full text  Abstract

36. Manickam P, Nagaraju B, Selvaraj V, et al; Team of Study Investigators. Efficacy of single-dose chemotherapy (rifampicin, oflaxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial. Indian J Lepr. 2012;84:195-207. Abstract

37. Cunha Mda G, Virmond M, Schettini AP, et al. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Lepr Rev. 2012;83:261-268. Abstract

38. International Leprosy Association. Report of the International Leprosy Association Technical Forum: Paris, France, 22-28 February 2002. Int J Lepr Other Mycobact Dis. 2002;70(suppl):S1-S62. Abstract

39. Consigny S, Bentoucha A, Bonnafous P, et al. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2000;44:2919-2921.Full text  Abstract

40. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227. Abstract

41. WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.Full text  Abstract

42. WHO Regional Office for South-East Asia. Enhanced global strategy for further reducing the disease burden due to leprosy (plan period 2011-2015). 2009 [internet publication].Full text

43. International Federation of Anti-Leprosy Associations. ILEP learning guide 4: how to prevent disability in leprosy. 2006 [internet publication].Full text

Use of this content is subject to our disclaimer